(NASDAQ: LPCN) Lipocine's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.53%.
Lipocine's earnings in 2026 is -$11,851,405.On average, 4 Wall Street analysts forecast LPCN's earnings for 2026 to be -$12,992,118, with the lowest LPCN earnings forecast at -$12,523,020, and the highest LPCN earnings forecast at -$13,330,957. On average, 4 Wall Street analysts forecast LPCN's earnings for 2027 to be -$11,268,245, with the lowest LPCN earnings forecast at -$13,330,957, and the highest LPCN earnings forecast at -$8,916,160.
In 2028, LPCN is forecast to generate -$7,988,681 in earnings, with the lowest earnings forecast at -$7,675,400 and the highest earnings forecast at -$8,223,642.